US equities
|
SPCX
$141.31
▲+0.00%
AMD
$483.90
▲+0.00%
MU
$855.10
▲+0.00%
TSLA
$398.50
▲+0.00%
NVDA
$206.69
▲+0.00%
SNDK
$1,126.52
▲+0.00%
AMZN
$250.69
▲+0.00%
GOOGL
$280.03
▲+0.00%
SPCX
$141.31
▲+0.00%
AMD
$483.90
▲+0.00%
MU
$855.10
▲+0.00%
TSLA
$398.50
▲+0.00%
NVDA
$206.69
▲+0.00%
SNDK
$1,126.52
▲+0.00%
AMZN
$250.69
▲+0.00%
GOOGL
$280.03
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Akamis Bio
Akamis Bio to Present Data from a Phase 1 Study of NG-348 in Patients with Advanced Epithelial Tumors at SITC 2026
November 03, 2026
From
Akamis Bio
Via
Business Wire
Akamis Bio Completes Enrollment of the Phase 1b FORTRESS Study of NG-350A in Mismatch Repair-Proficient Locally Advanced Rectal Cancer
October 14, 2026
From
Akamis Bio
Via
Business Wire
Akamis Bio Announces Encouraging Preliminary Results from the Phase 1b FORTRESS Study of NG-350A in Mismatch Repair-Proficient Locally Advanced Rectal Cancer
April 17, 2026
From
Akamis Bio
Via
Business Wire
Akamis Bio to Present Initial Data from the Phase 1b FORTRESS Study of NG-350A in Mismatch Repair-Proficient Locally Advanced Rectal Cancer at AACR 2026
March 17, 2026
From
Akamis Bio
Via
Business Wire
Akamis Bio Receives FDA Fast Track Designation for NG-350A for the Treatment of Mismatch Repair-Proficient Locally Advanced Rectal Cancer
October 14, 2025
From
Akamis Bio
Via
Business Wire
Akamis Bio Announces the Appointment of Andrew Hirsch to the Company’s Board of Directors
August 12, 2025
From
Akamis Bio
Via
Business Wire
Akamis Bio Broadens Leadership Team with Key Executive Appointments
May 06, 2025
From
Akamis Bio
Via
Business Wire
Akamis Bio Announces Enrollment of First Patient in Phase 1b FORTRESS Trial of NG-350A in Patients with Locally Advanced Rectal Cancer
April 03, 2025
From
Akamis Bio
Via
Business Wire
Akamis Bio Announces $60 Million in Funding Linked to Series A Prime Financing and New Strategic Partnership
December 17, 2024
From
Akamis Bio
Via
Business Wire
Akamis Bio Announces Publication Detailing Initial Proof of Mechanism for NG-350A, an IV-Dosed Tumor Gene Therapy Delivering a CD40 Agonist Payload
October 23, 2024
From
Akamis Bio
Via
Business Wire
Akamis Bio Highlights Data Showing Potential of its Adenovirus Vector Technology in Combination with Radiation to Treat Advanced Rectal Cancer
October 03, 2023
From
Akamis Bio
Via
Business Wire
Akamis Bio Strengthens Leadership Team with Key Executive Appointments
July 06, 2023
From
Akamis Bio
Via
Business Wire
Akamis Bio, Parker Institute for Cancer Immunotherapy, and Cancer Research Institute Announce Expanded Partnership to Advance Novel Treatments for Pancreatic Cancer
February 16, 2023
From
Akamis Bio
Via
Business Wire
Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics
January 05, 2023
From
Akamis Bio
Via
Business Wire
